JP2006519858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006519858A5 JP2006519858A5 JP2006508945A JP2006508945A JP2006519858A5 JP 2006519858 A5 JP2006519858 A5 JP 2006519858A5 JP 2006508945 A JP2006508945 A JP 2006508945A JP 2006508945 A JP2006508945 A JP 2006508945A JP 2006519858 A5 JP2006519858 A5 JP 2006519858A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- substituted
- substituents
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- 239000008194 pharmaceutical composition Substances 0.000 claims 38
- 125000001424 substituent group Chemical group 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 13
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 12
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims 11
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 10
- -1 carboxy, hydroxy Chemical group 0.000 claims 9
- 230000003287 optical effect Effects 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000002947 alkylene group Chemical group 0.000 claims 8
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 6
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 6
- 230000005856 abnormality Effects 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 125000004419 alkynylene group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims 5
- 208000010412 Glaucoma Diseases 0.000 claims 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000017442 Retinal disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- 230000001537 neural effect Effects 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000017497 prostate disease Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 125000004957 naphthylene group Chemical group 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- LXECNSMYNFWFCZ-UHFFFAOYSA-N 3-(1-oxo-3,4-dihydroisothiochromen-8-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=3C(=O)SCCC=3C=CC=2)=C1 LXECNSMYNFWFCZ-UHFFFAOYSA-N 0.000 claims 1
- OPWFMUIGBAFGOP-UHFFFAOYSA-N 3-(1-oxo-3,4-dihydrothiopyrano[3,4-b]indol-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(N2C3=CC=CC=C3C3=C2C(SCC3)=O)=C1 OPWFMUIGBAFGOP-UHFFFAOYSA-N 0.000 claims 1
- YYXJMOQAESRPSE-UHFFFAOYSA-N 3-(2-oxothian-3-yl)propanoic acid Chemical compound OC(=O)CCC1CCCSC1=O YYXJMOQAESRPSE-UHFFFAOYSA-N 0.000 claims 1
- HNFONZNDOVCFPB-UHFFFAOYSA-N 3-[(1-oxo-3,4-dihydroisothiochromen-8-yl)oxymethyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C=3C(=O)SCCC=3C=CC=2)=C1 HNFONZNDOVCFPB-UHFFFAOYSA-N 0.000 claims 1
- SWZSGEFGQYYIGV-UHFFFAOYSA-N 3-[(2-oxothian-3-yl)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CC2C(SCCC2)=O)=C1 SWZSGEFGQYYIGV-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- SVOTYRUYQODXTA-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=C(C=CC=C1)C1=CC=CC=2C3=CC=CC=C3C12 Chemical group C(C1=CC=CC=C1)OC1=C(C=CC=C1)C1=CC=CC=2C3=CC=CC=C3C12 SVOTYRUYQODXTA-UHFFFAOYSA-N 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 208000007222 Physiological Sexual Dysfunction Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000007074 memory dysfunction Effects 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 230000009689 neuronal regeneration Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 0 OC(*IC(**S1)C1=O)=O Chemical compound OC(*IC(**S1)C1=O)=O 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45064803P | 2003-03-03 | 2003-03-03 | |
| US60/450,648 | 2003-03-03 | ||
| PCT/US2004/006178 WO2004078742A1 (en) | 2003-03-03 | 2004-03-03 | Thiolactones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006519858A JP2006519858A (ja) | 2006-08-31 |
| JP2006519858A5 true JP2006519858A5 (enExample) | 2008-06-26 |
| JP4773951B2 JP4773951B2 (ja) | 2011-09-14 |
Family
ID=32962505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508945A Expired - Fee Related JP4773951B2 (ja) | 2003-03-03 | 2004-03-03 | チオラクトン |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7125907B2 (enExample) |
| EP (2) | EP1988088A1 (enExample) |
| JP (1) | JP4773951B2 (enExample) |
| AT (1) | ATE433445T1 (enExample) |
| AU (1) | AU2004217969B2 (enExample) |
| CA (1) | CA2518234C (enExample) |
| CY (1) | CY1109356T1 (enExample) |
| DE (1) | DE602004021476D1 (enExample) |
| DK (1) | DK1599461T3 (enExample) |
| ES (1) | ES2326083T3 (enExample) |
| MX (1) | MXPA05009492A (enExample) |
| PL (1) | PL1599461T3 (enExample) |
| PT (1) | PT1599461E (enExample) |
| SI (1) | SI1599461T1 (enExample) |
| WO (1) | WO2004078742A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125907B2 (en) | 2003-03-03 | 2006-10-24 | Guilford Pharmaceuticals Inc. | Thiolactones |
| US20080287866A1 (en) * | 2007-01-31 | 2008-11-20 | Adam Heller | Methods and compositions for the treatment of pain |
| WO2017029399A1 (en) | 2015-08-20 | 2017-02-23 | Universität Zu Köln | Pain tracking by pet-imaging (pain-trap) |
| WO2021155167A1 (en) * | 2020-01-31 | 2021-08-05 | The Johns Hopkins University | Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239636A (en) * | 1978-10-23 | 1980-12-16 | Exxon Research & Engineering Co. | Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions |
| JPH0532659A (ja) * | 1991-08-01 | 1993-02-09 | Tsumura & Co | 糖尿病治療剤 |
| GB9218810D0 (en) | 1992-09-04 | 1992-10-21 | Univ Birmingham | Antiviral pyrimidine nucleosides |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| GB9602721D0 (en) | 1996-02-09 | 1996-04-10 | Pharmacia Spa | Biologically active ureido derivatives useful in the treatment of multiple sclerosis |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| TR199802638T2 (xx) | 1996-06-17 | 1999-03-22 | Guilford Pharmaceuticals, Inc. | Kanser tedavisinde naaladase inhibit�rleri kullan�m�. |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| US6071965A (en) | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| GB9615202D0 (en) | 1996-07-19 | 1996-09-04 | Smithkline Beecham Plc | Pharmaceuticals |
| PL332413A1 (en) | 1996-09-27 | 1999-09-13 | Guilford Pharm Inc | Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| EP1093453B1 (en) * | 1998-07-06 | 2005-09-28 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| US6265609B1 (en) * | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
| US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| US6479470B1 (en) * | 1999-04-28 | 2002-11-12 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase |
| US6228888B1 (en) * | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
| US6348464B1 (en) | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
| AU6661901A (en) | 2000-05-30 | 2001-12-11 | Guilford Pharm Inc | Naaladase inhibitors for treating retinal disorders and glaucoma |
| WO2001091738A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| WO2001092273A2 (en) | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| ES2288550T3 (es) * | 2001-01-08 | 2008-01-16 | Pathway Intermediates Limited | Compuestos autoinductores y sus utilizaciones. |
| FR2819253B1 (fr) | 2001-01-11 | 2004-12-03 | Servier Lab | Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP4234430B2 (ja) * | 2001-01-17 | 2009-03-04 | エムジーアイ ジーピー インコーポレイティッド | チオールを含むｎａａｌａｄアーゼ抑制物質 |
| JP4625236B2 (ja) | 2001-05-11 | 2011-02-02 | エーザイ インコーポレーテッド | ＮＡＡＬＡＤａｓｅ阻害剤としてのヒドロキサム酸およびアシルヒドロキサミン |
| PT1406867E (pt) | 2001-05-30 | 2009-02-25 | Eisai Corp North America | Derivados do ácido tiolalquilbenzóico |
| US20050080139A1 (en) | 2001-12-28 | 2005-04-14 | Slusher Barbara S. | Naaladase inhibitors for treating huntington's disease |
| WO2004078180A2 (en) | 2003-03-03 | 2004-09-16 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating opioid tolerance |
| US7125907B2 (en) | 2003-03-03 | 2006-10-24 | Guilford Pharmaceuticals Inc. | Thiolactones |
-
2004
- 2004-03-03 US US10/791,278 patent/US7125907B2/en not_active Expired - Fee Related
- 2004-03-03 DK DK04716834T patent/DK1599461T3/da active
- 2004-03-03 EP EP08013761A patent/EP1988088A1/en not_active Withdrawn
- 2004-03-03 AU AU2004217969A patent/AU2004217969B2/en not_active Ceased
- 2004-03-03 PL PL04716834T patent/PL1599461T3/pl unknown
- 2004-03-03 PT PT04716834T patent/PT1599461E/pt unknown
- 2004-03-03 ES ES04716834T patent/ES2326083T3/es not_active Expired - Lifetime
- 2004-03-03 CA CA2518234A patent/CA2518234C/en not_active Expired - Fee Related
- 2004-03-03 AT AT04716834T patent/ATE433445T1/de active
- 2004-03-03 SI SI200431195T patent/SI1599461T1/sl unknown
- 2004-03-03 MX MXPA05009492A patent/MXPA05009492A/es active IP Right Grant
- 2004-03-03 DE DE602004021476T patent/DE602004021476D1/de not_active Expired - Lifetime
- 2004-03-03 EP EP04716834A patent/EP1599461B1/en not_active Expired - Lifetime
- 2004-03-03 WO PCT/US2004/006178 patent/WO2004078742A1/en not_active Ceased
- 2004-03-03 JP JP2006508945A patent/JP4773951B2/ja not_active Expired - Fee Related
-
2006
- 2006-10-02 US US11/537,979 patent/US20070037798A1/en not_active Abandoned
-
2007
- 2007-07-30 US US11/830,737 patent/US7553866B2/en not_active Expired - Fee Related
-
2009
- 2009-05-26 US US12/472,251 patent/US7968593B2/en not_active Expired - Fee Related
- 2009-08-28 CY CY20091100904T patent/CY1109356T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11708319B2 (en) | Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers | |
| JP5422782B1 (ja) | 脳内に蓄積したタウタンパク質をイメージングするための新規化合物 | |
| JP2004524294A5 (enExample) | ||
| JP6509897B2 (ja) | 抗真菌化合物の調製方法 | |
| US8710100B2 (en) | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | |
| JP2002518374A (ja) | 治療用ビアリール誘導体 | |
| US11667606B2 (en) | Thyromimetics | |
| US11584728B2 (en) | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | |
| JP7184241B2 (ja) | ベンズヒドリルチオアセトアミド化合物を有効成分として含む線維化疾患の治療用組成物 | |
| JP2006519858A5 (enExample) | ||
| CN106999456A (zh) | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 | |
| US7220880B2 (en) | Amide linker peroxisome proliferator activated receptor modulators | |
| US20170121268A1 (en) | Ppar modulators | |
| CA3195037A1 (en) | New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium | |
| JP2005503353A5 (enExample) | ||
| CA2518234A1 (en) | Thiolactones | |
| CA2448089A1 (en) | Thiolalkyl benzoic acid derivatives | |
| EP3119768B1 (en) | 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer | |
| US10759735B2 (en) | Bridged bicyclic compounds and their derivatives as neuroprotective agents and methods of use thereof | |
| CN113272271A (zh) | 大麻萜酚醌酸和其盐 | |
| CA2564092A1 (en) | Methods and compositions for the treatment of polycystic diseases | |
| CA2717495C (en) | Fullerene therapies for inflammation | |
| TR2021022289A2 (tr) | Ti̇p 2 diabetes mellitus hastaliğinin tedavi̇si̇ i̇çi̇n bi̇r i̇laç ve bu i̇lacin nanoparti̇külü | |
| WO2011075935A1 (zh) | 二苯基乙烯类衍生物及其用途 | |
| US8354548B2 (en) | Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase |